Floatz Rating
BB68/100
Confidence
Indicative
Sponsor
Ali Aminian
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
74High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07027969CT.gov Metabolic Surgery for Atrial Fibrillation Elimination | — | Not Yet Recruiting | — | — | — |
NCT07342764CT.gov Dapagliflozin Versus Metformin for the Management of Antipsychotic-Induced Weight Gain: A Pragmatic Pilot Randomized Controlled Trial | — | Not Yet Recruiting | — | — | — |
NCT07654179CT.gov Metformin as Adjunct Therapy in Depression-Obesity Comorbidity: Clinical and Genetic Evaluation | — | Active Not Recruiting | — | — | — |
NCT07485764CT.gov Metformin Combined With Secukinumab for Moderate-to-Severe Plaque Psoriasis in Overweight or Obese Chinese Patients | — | Not Yet Recruiting | — | — | — |
NCT07550816CT.gov Drug-drug Interaction Study of ZT002 Injection in Overweight and Obese Participants | — | Not Yet Recruiting | — | — | — |
NCT07502001CT.gov Influence of HDM1005 on Gastric Emptying and Pharmacokinetics of Metformin, Atorvastatin, Warfarin, and Digoxin | — | Not Yet Recruiting | — | — | — |
NCT07225816CT.gov Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected) | — | Recruiting | — | — | — |
NCT03686657CT.gov Evaluation of Superiority of Valsartan+Celecoxib+Metformin Over Metformin Alone in Type 2 Diabetes Patients | — | Not Yet Recruiting | — | — | — |
NCT07331389CT.gov A Drug-Drug Interaction Study of HDM1002 and Metformin, Empagliflozin, Midazolam, Valsartan, and Warfarin | — | Recruiting | — | — | — |
NCT07120828CT.gov The Role of CYP8B1 Polymorphisms in Modulating the Biochemical Pathways Affected by SGLT2 Inhibitors in T2DM and Obesity | — | Completed | — | — | — |
Show 115 more trialsShow fewer
NCT07293325CT.gov Semaglutide and Tirzepatide for Genetic Aging Delay in Adults With Obesity | — | Recruiting | — | — | — |
NCT06742710CT.gov Liraglutide Treatment in Obese Infertile PCOS Women | — | Recruiting | — | — | — |
NCT07362030CT.gov Drug-durg Interaction of RAY1225 With Warfarin, Atorvastatin, Metformin and Digoxin | — | Active Not Recruiting | — | — | — |
NCT06920056CT.gov A Study of BGM0504 in Overweight or Obese Participants | — | Completed | — | — | — |
NCT06775093CT.gov Effects of GLP-1RAs on Reproductive Outcomes in PCOS and Obesity | — | Not Yet Recruiting | — | — | — |
NCT06896981CT.gov Semaglutide in Women With Polycystic Ovary Syndrome and Obesity | — | Recruiting | — | — | — |
NCT06860841CT.gov Effects of D-Chiro-Inositol Combined with Metformin on Insulin Resistance in People with Overweight or Obesity and T2DM | — | Active Not Recruiting | — | — | — |
NCT06273072CT.gov Metformin IN Asthma for Overweight and Obese Individuals (MINA) | — | Recruiting | — | — | — |
NCT06605703CT.gov A Randomized Controlled Trial Comparing the Effectiveness of Different Treatment Options for Weight Management After Discontinuation of Semaglutide and Tirzepatide (GLP1 Transition Trial) | — | Completed | — | — | — |
NCT06438146CT.gov LIROH - Liraglutide for Obesity in HIV | — | Unknown | — | — | — |
NCT06000462CT.gov The Effect of Dapagliflozin on Weight Loss in Obese Adults Without Diabetes | — | Active Not Recruiting | — | — | — |
NCT06283641CT.gov Study to Evaluate the Safety and Effectiveness of Saxenda® for Weight Management in Routine Clinical Practice in Taiwan. | — | Completed | — | — | — |
NCT06216340CT.gov Efficacy of Henagliflozin for Weight Loss in Obesity Without Diabetes | — | Not Yet Recruiting | — | — | — |
NCT05949008CT.gov Effect of Metformin, a Drug Used to Treat Diabetes, vs Placebo | — | Active Not Recruiting | — | — | — |
NCT06501326CT.gov Efficacy and Safety of Liraglutide in the Treatment of Obesity Combined With Metabolism Associated Fatty Liver Disease | — | Unknown | — | — | — |
NCT05952882CT.gov Liraglutide and Metformin Combination on Weight Loss, Metabolic - Endocrine Parameters and Pregnancy Rate in Women With PCOS, Obesity and Infertility | — | Unknown | — | — | — |
NCT06247748CT.gov Influence of JY09 on Pharmacokinetics of Metformin , Rosuvastatin , and Digoxin and the QT Interval Study in Overweight Chinese Subjects | — | Completed | — | — | — |
NCT06059287CT.gov The Effect of Henagliflozin and Metformin on Myocardial Tissue-level Characteristics | — | Unknown | — | — | — |
NCT04194424CT.gov A Multidisciplinary Weight Loss Program at AUB-MC | — | Active Not Recruiting | — | — | — |
NCT05756764CT.gov Anti-obesity Pharmacotherapy and Inflammation | — | Active Not Recruiting | — | — | — |
NCT05815680CT.gov A Study to Evaluate the Drug-drug Interactions (DDIs) of IBI362 With Metformin, Warfarin, Atorvastatin, Digoxin in Overweight or Obese Subjects | — | Completed | — | — | — |
NCT05438186CT.gov INSPIRE Turkey :A Research Study Looking at the Clinical Parameters Associated With Use and Discontinuation of Saxenda® in Local Clinical Practice in Turkey by Analysing Past Patient Medical Records | — | Withdrawn | — | — | — |
NCT05268627CT.gov Endoscopic Ultrasound Guided Gastric Botulinum Toxin Injections Versus Glucagon Like Peptide 1 Receptor Agonist in Weight Loss | — | Unknown | — | — | — |
NCT04883346CT.gov Liraglutide (Saxenda(R)) in Adolescents With Obesity After Sleeve Gastrectomy | — | Completed | — | — | — |
NCT04775082CT.gov SCALE KIDS: Research Study to Look at How Well a New Medicine is at Lowering Weight in Children With Obesity | — | Active Not Recruiting | — | — | — |
NCT04529278CT.gov Efficacy and Tolerance of Liraglutide for Weight Loss in Obese Type 2 Diabetic Hemodialysis Patients | — | Unknown | — | — | — |
NCT02920190CT.gov Antigen-Lipid-Driven Monoclonal Gammopathies Targeting Epicardial Fat | — | Withdrawn | — | — | — |
NCT04311411CT.gov A Study of Tirzepatide in Overweight and Very Overweight Participants | — | Completed | — | — | — |
NCT04605861CT.gov The Efficacy and Safety of Liraglutide on Body Weight Loss in Obese and Overweight Patients | — | Completed | — | — | — |
NCT05821543CT.gov Efficacy and Safety of Sibutramin-containing Drugs in Patient With Alimentary Obesity | — | Completed | — | — | — |
NCT04525300CT.gov Gut Microbiome Changes Following Liraglutide Treatment in Obese Subjects or Overweight Subjects With Co-morbidities | — | Unknown | — | — | — |
NCT04487743CT.gov Efficacy and Safety of Liraglutide on Body Weight in Obese Subjects or Overweight Subjects With Co-morbidities | — | Unknown | — | — | — |
NCT04829903CT.gov Dulaglutide Versus Liraglutide in Obese Type 2 Diabetic Adolescents Using Metformin | — | Completed | — | — | — |
NCT03986008CT.gov Effects of Benaglutide on Weight and Gut Microbiota in Obese Patients | — | Unknown | — | — | — |
NCT03710460CT.gov Effect of Dapagliflozin/Metformin XR vs Monotherapies on Anthropometric Indicators in Obesity | — | Unknown | — | — | — |
NCT03898037CT.gov Effect of Lifestyle and/or Metformin Intervention on Pregnancy Outcome, A Pilot Randomized Controlled Trial | — | Completed | — | — | — |
NCT03961659CT.gov Effects of Liraglutid, Dapagliflozin and Acarbose on the Cognitive Function, Olfactory Function, and Odor-induced Brain Activation in Overweight/Obese T2DM Patients Controlled Inadequately With Metformin Monotherapy. | — | Unknown | — | — | — |
NCT03603080CT.gov Efficacy of Pharmacotherapy to Enhance Weight Loss Following Sleeve Gastrectomy | — | Terminated | — | — | — |
NCT03087032CT.gov Liraglutide-bolus vs Glargine-bolus Therapy in Overweight/Obese Type 2 Diabetes Patients (LiraGooD) | — | Recruiting | — | — | — |
NCT03757130CT.gov Multiple Ascending Dose Study of AMG 598 in Adults With Obesity | — | Completed | — | — | — |
NCT03671733CT.gov Effects of GLP-1 RAs on Weight and Metabolic Indicators in Obese Patients | — | Unknown | — | — | — |
NCT03560336CT.gov A Regulatory Post-marketing Surveillance (rPMS) Study to Evaluate the Safety and Effectiveness of Saxenda®(Liraglutide 3.0 mg) in Obese Patients and Overweight Patients With Obesity-related Comorbidities in Routine Clinical Practice in Korea. | — | Completed | — | — | — |
NCT03479762CT.gov In Market Utilisation of Liraglutide Used for Weight Management in the UK: a Study in the CPRD Primary Care Database | — | Completed | — | — | — |
NCT03486392CT.gov A Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Non-diabetic Severely Obese Participants | — | Completed | — | — | — |
NCT03419624CT.gov The Potential of Dapagliflozin Plus Exenatide in Obese Insulin-resistant Patients | — | Terminated | — | — | — |
NCT03593668CT.gov Effect and Safety of Benaglutide or Metformin in Patients With Simple Obesity Who Have Inadequate Weight Control | — | Unknown | — | — | — |
NCT03374956CT.gov Individualized Obesity Pharmacotherapy | — | Completed | — | — | — |
NCT04839237CT.gov The Effect and the Pharmacogenomics Study of Liraglutide in Obese Patients | — | Withdrawn | — | — | — |
NCT03523273CT.gov Pilot Study of the Effect of Liraglutide 3.0 mg on Weight Loss and Gastric Functions in Obesity | — | Completed | — | — | — |
NCT03352869CT.gov Research of Exenatide for Overweight/Obese PCOS Patients With IGR | — | Completed | — | — | — |
NCT03151005CT.gov The Effect of GLP-1 Agonists Versus OCs on Reproductive Disorders and Cardiovascular Risks in Overweight PCOS | — | Completed | — | — | — |
NCT03101930CT.gov Cardiovascular Effects of GLP-1 Receptor Activation | — | Completed | — | — | — |
NCT03158805CT.gov Saxenda® in Obese or Overweight Patients With Stable Bipolar Disorder (Investigator Initiated) | — | Completed | — | — | — |
NCT03041792CT.gov Methodology Study To Examine 6-Week Food Intake With Liraglutide In Obese Subjects | — | Completed | — | — | — |
NCT02963935CT.gov Effect and Safety of Liraglutide 3.0 mg as an Adjunct to Intensive Behaviour Therapy for Obesity in a Non-specialist Setting | — | Completed | — | — | — |
NCT02967757CT.gov In-market Utilisation of Liraglutide Used for Weight Management in Europe | — | Completed | — | — | — |
NCT02944500CT.gov Saxenda: Underlying Mechanisms and Clinical Outcomes | — | Active Not Recruiting | — | — | — |
NCT02918279CT.gov Effect of Liraglutide for Weight Management in Pubertal Adolescent Subjects With Obesity | — | Completed | — | — | — |
NCT02796144CT.gov MEtformin and Lorcaserin for WeighT Loss in Schizophrenia | — | Terminated | — | — | — |
NCT02743598CT.gov Liraglutide for HIV-associated Neurocognitive Disorder | — | Terminated | — | — | — |
NCT04122716CT.gov Combined Effects of GLP-1 Analogue and Exercise on Maintenance of Weight Loss and Health After Very-low Calorie Diet | — | Unknown | — | — | — |
NCT02870231CT.gov Investigating Safety, Tolerability, PK and PD for Multiple Doses of NNC9204-0530 in Combination With Liraglutide in Male and Female Subjects Being Overweight or With Obesity | — | Completed | — | — | — |
NCT02745886CT.gov Metformin Induces a Dietary Restriction-like State in Human | — | Unknown | — | — | — |
NCT02717858CT.gov A Trial to Assess the Effects of Liraglutide on Gallbladder Emptying in Overweight and Obese Subjects. | — | Completed | — | — | — |
NCT02696148CT.gov A Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Liraglutide in Obese Children Aged 7 to 11 Years | — | Completed | — | — | — |
NCT02695810CT.gov The PRE-D Trial: Effect of Dapagliflozin, Metformin and Physical Activity in Pre-diabetes | — | Completed | — | — | — |
NCT02647944CT.gov Pilot Study of the Effect of Liraglutide on Weight Loss and Gastric Functions in Obesity | — | Completed | — | — | — |
NCT02527200CT.gov Effect of Liraglutide for Weight Management in Paediatric Subjects With Prader-Willi Syndrome | — | Completed | — | — | — |
NCT02909933CT.gov Low Dose Liraglutide and Metformin vs. High Dose Liraglutide Alone in Treatment of Obesity | — | Completed | — | — | — |
NCT02503943CT.gov Effects of Incretin on the Blood Pressure and Lipid in Patients With Overweight or Obese Diabetes | — | Unknown | — | — | — |
NCT03619330CT.gov Testosterone Replacement Therapy and Liraglutide Effects on Weight Loss in Hypogonadism. | — | Completed | — | — | — |
NCT02235961CT.gov Investigate Safety, Tolerability and Pharmacokinetics for Single Doses of NNC9204-0530 Alone and in Combination With Liraglutide in Overweight to Obese But Otherwise Healthy Male Subjects | — | Completed | — | — | — |
NCT03353948CT.gov The Effect of a Liraglutide on IVF in Obese PCOS | — | Completed | — | — | — |
NCT02207348CT.gov Investigating Bioequivalence Between Single-dose Liraglutide Administered Subcutaneously With Two Different Pen-injectors | — | Completed | — | — | — |
NCT02082496CT.gov GLP-1 Response and Effect in Individuals With Obesity Causing Genetic Mutations | — | Completed | — | — | — |
NCT03034941CT.gov Short Term Weight Loss With Liraglutide and Metformin in Infertile Obese PCOS Patients | — | Completed | — | — | — |
NCT02014740CT.gov Effect of Liraglutide on Epicardial Fat in Subjects With Type 2 Diabetes | — | Completed | — | — | — |
NCT02187250CT.gov PDE-4 Inhibitor Roflumilast and GLP-1 Agonist Liraglutide in Polycystic Ovary Syndrome | — | Completed | — | — | — |
NCT02674893CT.gov Effect of Victoza on Dietary Preferences and Habit in Patients With Type 2 Diabetes | — | Terminated | — | — | — |
NCT02483299CT.gov Liraglutide as Add on Therapy on Metformin in Women With Polycystic Ovary Syndrome | — | Completed | — | — | — |
NCT02037672CT.gov PDE-4 Inhibitor Roflumilast and Polycystic Ovary Syndrome | — | Completed | — | — | — |
NCT01918865CT.gov Safety, Tolerability, and Efficacy of ISIS-PTP1BRx in Type 2 Diabetes | — | Completed | — | — | — |
NCT02514629CT.gov Testosterone, Metformin, or Both, for Hypogonadism in Obese Males | — | Completed | — | — | — |
NCT02055014CT.gov Randomisation to Endobarrier Alone Versus With Incretin Analogue in SustainEd Diabesity (REVISE-Diabesity) | — | Unknown | — | — | — |
NCT01725126CT.gov To Investigate the Safety, Tolerability and Pharmacodynamics of GSK2890457 in Healthy Volunteers and Subjects With Type 2 Diabetes | — | Completed | — | — | — |
NCT01789086CT.gov A Randomised, Double-blind, Placebo-controlled Trial to Assess Safety, Tolerability and Pharmacokinetics of Liraglutide in Obese Adolescent Subjects Aged 12 to 17 Years | — | Completed | — | — | — |
NCT01701973CT.gov Effect of DPP4 Inhibition on Growth Hormone Secretion | — | Completed | — | — | — |
NCT01557166CT.gov Effect of Liraglutide in Obese Subjects With Moderate or Severe Obstructive Sleep Apnoea: SCALE™ - Sleep Apnoea | — | Completed | — | — | — |
NCT01612468CT.gov Liraglutide in Type 1 Diabetes | — | Completed | — | — | — |
NCT01505673CT.gov Adding Liraglutide to High Dose Insulin: Breaking the Cycle | — | Completed | — | — | — |
NCT01675310CT.gov Medical Nutrition Therapy Plus Transgestational Metformin For Preventing Gestational Diabetes In High Risk Mexican Women | — | Completed | — | — | — |
NCT01911468CT.gov Polycystic Ovary Syndrome and Liraglutide as Add-on Therapy on Metformin | — | Completed | — | — | — |
NCT01899430CT.gov Polycystic Ovary Syndrome and Liraglutide | — | Completed | — | — | — |
NCT01272232CT.gov Effect of Liraglutide on Body Weight in Overweight or Obese Subjects With Type 2 Diabetes: SCALE™ - Diabetes | — | Completed | — | — | — |
NCT01272219CT.gov Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes | — | Completed | — | — | — |
NCT01384279CT.gov The Therapeutic Effects of Topiramate and Metformin on Second Generation Antipsychotics-induced Obesity | — | Completed | — | — | — |
NCT01351753CT.gov Drug Therapy Induced Weight Loss to Improve Blood Vessel Function in Subjects With Obesity | — | Terminated | — | — | — |
NCT01599338CT.gov Impact of Liraglutide on Sensory Perception, Sensory Specific Satiety, Liking and Wanting in Type 2 Diabetic Patients | — | Completed | — | — | — |
NCT02042664CT.gov Effect of GLP-1 Receptor (GLP-1R) Agonists on Cardiac Function and on Epicardial Adipose Tissue (EAT) Volume and on Myocardial TG Content in Obese Diabetics | — | Completed | — | — | — |
NCT01138930CT.gov Effect of Berberine on Hormonal and Metabolic Features in Obese Women With Polycystic Ovary Syndrome (PCOS) | — | Unknown | — | — | — |
NCT01122407CT.gov Pathophysiology of Cardiometabolic Risk Factors in African Americans | — | Completed | — | — | — |
NCT00978393CT.gov A Trial to Assess the Effect of Liraglutide on Gastric Emptying in Healthy Obese Volunteers | — | Completed | — | — | — |
NCT01107808CT.gov Calcium, Vitamin D and Metformin to Treat Insulin Resistance in Obese African American Adolescent Females | — | Withdrawn | — | — | — |
NCT00934570CT.gov Activity and Metformin Intervention in Obese Adolescents | — | Completed | — | — | — |
NCT00842400CT.gov A Drug Interaction Study of VI-0521 With Metformin, Sitagliptan and Probenecid in Healthy Subjects. | — | Completed | — | — | — |
NCT00775164CT.gov Pioglitazone Therapy in Obese Children With Insulin Resistance: A Randomized, Controlled Pilot Study | — | Withdrawn | — | — | — |
NCT00941382CT.gov Sibutramine-metformin Combination Versus Sibutramine and Metformin Monotherapy in Obese Patients | — | Unknown | — | — | — |
NCT00781937CT.gov Comparison of Liraglutide Versus Placebo in Weight Loss Maintenance in Obese Subjects: SCALE - Maintenance | — | Completed | — | — | — |
NCT00631033CT.gov DZX Mediated Insulin Suppression in Obese Men | — | Completed | — | — | — |
NCT00538486CT.gov A Randomized, Double-Blind, Active Control Trial Comparing Effects of Telmisartan, Candesartan and Amlodipine, Alone or Plus Metformin, on Non-Diabetic, Obese Hypertensive Patients | — | Completed | — | — | — |
NCT00618072CT.gov EMPOWIR:Enhance the Metabolic Profile of Women With Insulin Resistance | — | Completed | — | — | — |
NCT00422058CT.gov The Effect of Liraglutide on Body Weight in Obese Subjects Without Diabetes | — | Completed | — | — | — |
NCT00922194CT.gov Metformin in Overweight Type 2 Diabetes Mellitus | — | Completed | — | — | — |
NCT00349635CT.gov A Controlled-Study on the Effect of a Combination of Fenofibrate and Metformin on Weight Loss and Weight Loss-Maintenance, in Obese Patients. | — | Completed | — | — | — |
NCT03051451CT.gov Fixed Dose Combination of Fluoxetin and Metformin in the Management of Overweight and Obesity | — | Suspended | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Obesity Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Metformin (this asset) | Ali Aminian | Approved | BB · 68 |
| vi-0521 | VIVUS LLC | P4 | BBB |
| Tirzepatide | Royal North Shore Hospital | P4 | BBB |
| asc30 | Ascletis Pharma (China) Co., Limited | P2 | BBB |
| Phentermine | Russell McCulloh, MD | P4 | BBB |
| Survodutide | Boehringer Ingelheim | P3 | BBB |
| Deoxycholic Acid | University of California, San Diego | P4 | BBB |
| Efsubaglutide Alfa | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | P4 | BBB |
| Cagrilintide | Novo Nordisk A/S | P3 | BBB |
+42 more in the Obesity Disorder cohort
Other indications for Metformin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Prediabetes Syndrome | — | P4 | A · 81 |
| Gestational Diabetes | — | P4 | A · 81 |
| Diabetes Mellitus | — | P4 | A · 80 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Metformin in Obesity Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/metformin-obesity-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →